Navigating the Current Landscape of Non-Clear Cell Renal Cell Carcinoma: A Review of the Literature

被引:10
作者
John, Alexius [1 ,2 ]
Spain, Lavinia [2 ]
Hamid, Anis A. [1 ,2 ,3 ,4 ]
机构
[1] Eastern Hlth, Dept Med Oncol, Melbourne, Vic 3128, Australia
[2] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic 3000, Australia
[3] Monash Univ, Eastern Hlth Clin Sch, Melbourne, Vic 3128, Australia
[4] Univ Melbourne, Dept Surg, Melbourne, Vic 3010, Australia
关键词
non-clear cell; renal cell carcinoma; papillary; hereditary leiomyomatosis and renal cell cancer; chromophobe; medullary; collecting duct; COMPREHENSIVE MOLECULAR CHARACTERIZATION; OPEN-LABEL; PHASE-II; SUNITINIB; CABOZANTINIB; EPIDEMIOLOGY; MULTICENTER; MONOTHERAPY; EXPRESSION; CRIZOTINIB;
D O I
10.3390/curroncol30010070
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Non-clear cell renal cell carcinoma (nccRCC) is an entity comprised of a heterogeneous constellation of RCC subtypes. Genomic profiling has broadened our understanding of molecular pathogenic mechanisms unique to individual nccRCC subtypes. To date, clinical trials evaluating the use of immunotherapies and targeted therapies have predominantly been conducted in patients with clear cell histology. A comprehensive review of the literature has been undertaken in order to describe molecular pathogenic mechanisms pertaining to each nccRCC subtype, and concisely summarise findings from therapeutic trials conducted in the nccRCC space.
引用
收藏
页码:923 / 937
页数:15
相关论文
共 88 条
  • [21] Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma
    Choueiri, Toni K.
    Vaishampayan, Ulka
    Rosenberg, Jonathan E.
    Logan, Theodore F.
    Harzstark, Andrea L.
    Bukowski, Ronald M.
    Rini, Brian I.
    Srinivas, Sandy
    Stein, Mark N.
    Adams, Laurel M.
    Ottesen, Lone H.
    Laubscher, Kevin H.
    Sherman, Laurie
    McDermott, David F.
    Haas, Naomi B.
    Flaherty, Keith T.
    Ross, Robert
    Eisenberg, Peter
    Meltzer, Paul S.
    Merino, Maria J.
    Bottaro, Donald P.
    Linehan, W. Marston
    Srinivasan, Ramaprasad
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (02) : 181 - 186
  • [22] Epidemiology and risk factors for kidney cancer
    Chow, Wong-Ho
    Dong, Linda M.
    Devesa, Susan S.
    [J]. NATURE REVIEWS UROLOGY, 2010, 7 (05) : 245 - 257
  • [23] Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study
    Colomba, Emeline
    Le Teuff, Gwenael
    Eisen, Tim
    Stewart, Grant D.
    Fife, Kate
    Larkin, James
    Biondo, Andrea
    Pickering, Lisa
    Srinivasan, Anandagopal
    Boyle, Helen
    Derosa, Lisa
    Sternberg, Cora N.
    Recine, Federica
    Ralph, Christy
    Saldana, Carolina
    Barthelemy, Philippe
    Bernhard, Jean Christophe
    Gurney, Howard
    Verhoest, Gregory
    Vauleon, Elodie
    Bigot, Pierre
    Berger, Julien
    Pfister, Christian
    Gravis, Gwenaelle
    Rodier, Jean-Michel
    Culine, Stephane
    Caty, Armelle
    Rolland, Frederic
    Priou, Franck
    Escudier, Bernard
    Albiges, Laurence
    [J]. EUROPEAN JOURNAL OF CANCER, 2017, 80 : 55 - 62
  • [24] Conduit C, 2022, J CLIN ONCOL, V40
  • [25] The Somatic Genomic Landscape of Chromophobe Renal Cell Carcinoma
    Davis, Caleb F.
    Ricketts, Christopher J.
    Wang, Min
    Yang, Lixing
    Cherniack, Andrew D.
    Shen, Hui
    Buhay, Christian
    Kang, Hyojin
    Kim, Sang Cheol
    Fahey, Catherine C.
    Hacker, Kathryn E.
    Bhanot, Gyan
    Gordenin, Dmitry A.
    Chu, Andy
    Gunaratne, Preethi H.
    Biehl, Michael
    Seth, Sahil
    Kaipparettu, Benny A.
    Bristow, Christopher A.
    Donehower, Lawrence A.
    Wallen, Eric M.
    Smith, Angela B.
    Tickoo, Satish K.
    Tamboli, Pheroze
    Reuter, Victor
    Schmidt, Laura S.
    Hsieh, James J.
    Choueiri, Toni K.
    Hakimi, A. Ari
    Chin, Lynda
    Meyerson, Matthew
    Kucherlapati, Raju
    Park, Woong-Yang
    Robertson, A. Gordon
    Laird, Peter W.
    Henske, Elizabeth P.
    Kwiatkowski, David J.
    Park, Peter J.
    Morgan, Margaret
    Shuch, Brian
    Muzny, Donna
    Wheeler, David A.
    Linehan, W. Marston
    Gibbs, Richard A.
    Rathmell, W. Kimryn
    Creighton, Chad J.
    Signoretti, Sabina
    Seiler, Michael
    Chao, Hsu
    Dahdouli, Mike
    [J]. CANCER CELL, 2014, 26 (03) : 319 - 330
  • [26] Delahunt B, 2013, AM J SURG PATHOL, V37, P1490, DOI 10.1097/PAS.0b013e318299f0fb
  • [27] Renal Cell Carcinoma as a Metabolic Disease: An Update on Main Pathways, Potential Biomarkers, and Therapeutic Targets
    di Meo, Nicola Antonio
    Lasorsa, Francesco
    Rutigliano, Monica
    Loizzo, Davide
    Ferro, Matteo
    Stella, Alessandro
    Bizzoca, Cinzia
    Vincenti, Leonardo
    Pandolfo, Savio Domenico
    Autorino, Riccardo
    Crocetto, Felice
    Montanari, Emanuele
    Spilotros, Marco
    Battaglia, Michele
    Ditonno, Pasquale
    Lucarelli, Giuseppe
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (22)
  • [28] Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    Escudier, B.
    Porta, C.
    Schmidinger, M.
    Rioux-Leclercq, N.
    Bex, A.
    Khoo, V.
    Grunwald, V.
    Gillessen, S.
    Horwich, A.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 (05) : 706 - 720
  • [29] Open-label phase 2 trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysis
    Escudier, Bernard
    Molinie, Vincent
    Bracarda, Sergio
    Maroto, Pablo
    Szczylik, Cezary
    Nathan, Paul
    Negrier, Sylvie
    Weiss, Claudia
    Porta, Camillo
    Gruenwald, Viktor
    Albiges, Laurence
    [J]. EUROPEAN JOURNAL OF CANCER, 2016, 69 : 226 - 235
  • [30] Comprehensive review of chromophobe renal cell carcinoma
    Garje, Rohan
    Elhag, Dean
    Yasin, Hesham A.
    Acharya, Luna
    Vaena, Daniel
    Dahmoush, Laila
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2021, 160